Ligand Completes Acquisition of XOMA Royalty, Creating a Portfolio of More than 200 Biopharmaceutical Royalty Assets
Ligand Pharmaceuticals (Nasdaq: LGND) completed its acquisition of XOMA Royalty for $39.00 per share in cash, totaling about $739 million equity value, plus one CVR per share tied to 75% of net litigation proceeds. The deal adds seven commercial products and 100+ development assets, expanding its portfolio to 200+ royalties. Expected EPS accretion: +$0.50 (2026) and +$1.50 (2027).
How this was made
The 30-second read
Why it matters
The transaction is positioned as immediately accretive and adds quantified adjusted EPS contributions for 2026 and 2027, while also introducing CVR litigation-related uncertainty for XOMA Royalty holders.
Market read
Deal completion with cash consideration, portfolio expansion, and stated EPS accretion provides a concrete repricing catalyst for LGND, with CVR litigation as a key overhang.
What to watch
Integration execution and the timing of monetization across the 100+ development and commercial-stage assets may drive outcomes more than the headline portfolio size.
Background
Ligand is a biopharmaceutical royalty aggregator; it completed the acquisition of XOMA Royalty, expanding its royalty portfolio to 200+ assets.
Ticker impact
Ligand completed its acquisition of XOMA Royalty for $39.00 per share in cash, adding commercial and development royalty assets and EPS accretion.
Likely near-term positive bias as investors price in accretion and portfolio expansion, tempered by CVR litigation uncertainty.
The article discloses deal completion, consideration ($39/share), total equity value (~$739M), immediate accretion, and quantified EPS contribution, all of which can drive repricing. It also flags CVR litigation as a risk, limiting upside conviction.
Market effects
Reinforces consolidation/scale strategy in biopharma royalty aggregation, potentially supporting valuation multiples for similar royalty platforms.
Primarily US-listed biotech/royalty sentiment; limited direct regional spillover beyond US biotech investors.
Adds exposure to globally marketed products (e.g., Roche VABYSMO), which can broaden investor perception of international royalty revenue durability.
Counterpoint
The CVR tied to pending litigation could reduce realized proceeds versus the base-case, making the EPS accretion less certain than headline suggests.
Key entities
- companyLigand Pharmaceuticals Incorporated
Acquirer that completed the XOMA Royalty deal and will provide an updated 5-year outlook at Investor Day on Dec 8, 2026.
- companyXOMA Royalty Corporation
Royalty aggregator acquired by Ligand; its stock ceased trading on Nasdaq Global Market at closing.
- security_featureXOMA Royalty Contingent Value Right (CVR)
Non-transferable CVR entitling holders to 75% of net proceeds from certain pending litigation.
